Prior to joining Precirix, Dr. Almaula led business development at Advanced Accelerator Applications Inc., building the diagnostic and therapeutic radiopharmaceuticals pipeline preceding its USD 3.9bn acquisition by Novartis. Additionally, she has worked in search and evaluation at Nycomed, (now Takeda), alliance management for biosimilars at Dr Reddy’s Labs and in academic technology transfer at Rockefeller University. She started her career in biotechnology equity research, has a PhD in biochemistry and molecular biology from Rutgers University and conducted postdoctoral research in molecular neurobiology at Mount Sinai Medical Center.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.